Premium
Treatment of Ranula in Pediatric Patients with Intralesional Injection of OK‐432
Author(s) -
Lee HeungMan,
Lim HyunWoo,
Kang Hee Joon,
Chae SungWon,
Hwang SoonJae,
Jung KwangYoon,
Woo JeongSoo
Publication year - 2006
Publication title -
the laryngoscope
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.181
H-Index - 148
eISSN - 1531-4995
pISSN - 0023-852X
DOI - 10.1097/01.mlg.0000216809.90196.83
Subject(s) - ranula , medicine , sclerotherapy , surgery , complication , medical record , adverse effect , retrospective cohort study
Objective: To assess the efficacy of treatment of a ranula in children by intralesional injection of OK‐432. Study Design: Retrospective analysis of 13 cases. Methods: Review of medical records of pediatric patients with ranula treated by OK‐432 sclerotherapy from 2002 through 2005. Results: Among 13 cases, 9 were completely regressed by injection therapy alone. Three cases were incompletely regressed. One case was cured by surgical excision. The follow‐up duration was 6 to 46 (mean 24.3) months. Adverse effects of OK‐432 injection were tolerable, and no complication was observed. Conclusions: On the basis of our experience, sclerotherapy with OK‐432 was a safe and effective primary treatment for a ranula in children. Further study will be needed to conclude its long‐term effectiveness.